← PharmaCyte Biotech (PMCB)

PharmaCyte Biotech SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

  • 8-KNov. 13, 2026, 4:28 p.m. ETView on SEC.govOur explainer

    Material modification of security holders' rights · Amendments to articles or bylaws; fiscal year change · Other events · Financial statements and exhibits

    AI summary, unreviewedPharmaCyte Biotech (PMCB) to Effect 1-for-19 Reverse Stock Split Effective November 12, 2026 to Regain Nasdaq Minimum Bid Price Compliance

  • 8-KOct. 16, 2026, 5 p.m. ETView on SEC.gov

    Change in certifying accountant · Financial statements and exhibits

    AI summary, unreviewedPharmaCyte Biotech dismisses CBIZ CPAs as auditor, engages Grassi & Co. amid disclosed material weaknesses in internal controls